The 2013 annual meeting of the American Society of Hematology (ASH), which took place last month, featured many oral and poster presentations about Kyprolis, one of the newest drugs to be approved for the treat­ment of multiple myeloma.

The drug con­tinues to be tested in various com­bi­na­tions in both newly diag­nosed and re­lapsed/refractory multiple myeloma patients, as well as in patients with the myeloma precursor disease smol­der­ing myeloma.

In most trials, Kyprolis (car­filz­o­mib) was com­bined with dex­a­meth­a­sone …

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are …

A number of studies to be presented at this year’s American Society of Hema­tol­o­gy (ASH) meeting look at diseases that can progress to mul­ti­ple mye­lo­ma.

These 'myeloma precursor diseases,' as they are sometimes called, in­clude mono­clon­al gammopathy of undetermined significance (MGUS) and smoldering myeloma.

In today's ASH preview article, The Beacon turns its attention to myeloma pre­cursor diseases, reviewing the key studies about them that will be presented at ASH this weekend and early next …

This year’s Congress of the European Hematology Association (EHA) is cur­rent­ly being held in Stockholm. It started earlier this week and will run through Sunday, June 16.

A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster pre­sen­ta­tions.

This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and to­mor­row. A previous article covered the key findings that will be pre­sented …

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, …

During a session at the International Myeloma Workshop (IMW) held in Japan earlier this month, Dr. María-Victoria Mateos of the University Hospital in Sala­manca, Spain, discussed whether smoldering multiple myeloma patients should be actively treated.

The current standard of care is to monitor smoldering myeloma patients and to begin treatment only when their disease progresses to sympto­matic multiple myeloma.

However, in Dr. Mateos's opinion, smoldering myeloma patients who are at high risk of progressing to symptomatic myeloma …

A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal ab­nor­malities who did not re­spond to prior therapy.

The findings were presented by Dr. Paul Richardson of the Dana-Farber Cancer Institute in Boston at the International Myeloma Workshop (IMW) in Kyoto, Japan, this past Sunday.

In the new analysis, high-risk patients were defined as those with a deletion in chromosome 17 (del17p) or the …